FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions comprising an antisense oligomer for treating muscular dystrophy, and a pharmaceutical composition comprising said antisense oligomer for treating a patient suffering muscular dystrophy. In one embodiment, the antisense oligomer has length of 21 to 30 nucleotides and includes 15 nucleotides from the nucleotide sequence SEQ ID NO: 1, and also has activity causing skipping exon 51 in human dystrophin gene.
EFFECT: invention expands the range of means for treatment of muscular dystrophy.
12 cl, 1 dwg, 8 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2825834C2 |
| ANTISENSE NUCLEIC ACID | 2016 |
|
RU2724554C2 |
| ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2651468C1 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2702424C2 |
| ANTISENSE NUCLEIC ACIDS | 2015 |
|
RU2695430C2 |
| COMPOSITION CONTAINING ANTISENSE OLIGONUCLEOTIDE AND ITS USE FOR THE TREATMENT OF DUSCHENNE MUSCULAR DYSTROPHY | 2019 |
|
RU2799442C2 |
| MYOSTATIN SIGNAL INHIBITOR | 2019 |
|
RU2820270C2 |
| ANTISENSE NUCLEIC ACIDS | 2011 |
|
RU2567664C2 |
| ANTISENSE NUCLEIC ACIDS | 2012 |
|
RU2619184C2 |
| DEEP GLYCATION END PRODUCTS RECEPTOR MODULATORS AND MODULATION | 2020 |
|
RU2820247C2 |
